Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.85 |
| ▸ | MEN1 | O00255 | 1/20 | 0.85 |
| ▸ | ABL1 | P00519 | 1/20 | 0.85 |
| ▸ | LMNA | P02545 | 1/20 | 0.85 |
| ▸ | PKM | P14618 | 1/20 | 0.85 |
| ▸ | IDE | P14735 | 1/20 | 0.85 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.85 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.85 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.85 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.85 |
| ▸ | HLCS | P50747 | 6/20 | 0.60 |
| ▸ | CA12 | O43570 | 7/20 | 0.55 |
| ▸ | CA1 | P00915 | 7/20 | 0.55 |
| ▸ | CA2 | P00918 | 7/20 | 0.55 |
| ▸ | CA9 | Q16790 | 7/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Biotin SCHEMBL8432238 | 0.94 | TDP1 (0.76) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL7717405 | 0.94 | TDP1 (0.83) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL28516341 | 0.94 | TDP1 (0.92) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL9387622 | 0.94 | TDP1 (0.92) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL23722253 | 0.92 | TDP1 (0.90) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL1199492 | 0.92 | TDP1 (0.94) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL636444 | 0.92 | TDP1 (0.94) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL22943835 | 0.92 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL36572 | 0.92 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL21981206 | 0.92 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0088542-B1 | SKIN TREATMENT COMPOSITION | UNILEVER N.V. (NL) | 1988-05-11 | — | — | EP | claimed |
| US-11053279-B2 | Methods for the site-selective coupling of a first agent to a second agent | UNIVERSITEIT GENT (BE) | 2021-07-06 | — | — | US | disclosed |
| EP-3313858-B1 | METHODS FOR THE SITE-SELECTIVE COUPLING OF A FIRST AGENT TO A SECOND AGENT | UNIV GENT (BE) | 2019-09-25 | — | — | EP | disclosed |
| US-20190002494-A1 | METHODS FOR THE SITE-SELECTIVE COUPLING OF A FIRST AGENT TO A SECOND AGENT | UNIVERSITEIT GENT (BE) | 2019-01-03 | — | — | US | disclosed |
| EP-3313858-A1 | METHODS FOR THE SITE-SELECTIVE COUPLING OF A FIRST AGENT TO A SECOND AGENT | Universiteit Gent (BE) | 2018-05-02 | — | — | EP | disclosed |
| WO-2017001204-A1 | METHODS FOR THE SITE-SELECTIVE COUPLING OF A FIRST AGENT TO A SECOND AGENT | UNIVERSITEIT GENT (BE) | 2017-01-05 | — | — | WO | disclosed |
| US-5856571-A | Semicarbazide-containing linker compounds for formation of stably-linked conjugates and methods related thereto | CELLPRO, INCORPORATED (US) | 1999-01-05 | — | — | US | disclosed |
| WO-1996040263-A2 | SEMICARBAZIDE-CONTAINING LINKER COMPOUNDS FOR FORMATION OF STABLY-LINKED CONJUGATES AND METHODS RELATED THERETO | CELLPRO, INCORPORATED (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11053279-B2 | Methods for the site-selective coupling of a first agent to a second agent | PAICS, HNMT, DPYD | TDP1 2100/4885MEN1 1494/4885ABL1 474/4885 |
| US-20190002494-A1 | METHODS FOR THE SITE-SELECTIVE COUPLING OF A FIRST AGENT TO A SECOND AGENT | PAICS, HNMT, DPYD | TDP1 2100/4885MEN1 1494/4885ABL1 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.